Full Text View
Tabular View
No Study Results Posted
Related Studies
A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease
This study has been terminated.
( See termination reason in detailed description. )
Study NCT00912288   Information provided by Pfizer

First Received on June 1, 2009.   Last Updated on September 8, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Alzheimer Disease
More general conditions related to this trial
Brain Diseases
Central Nervous System Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Dementia
Mental Disorders
Nervous System Diseases
Neurodegenerative Diseases
Tauopathies
Interventions listed in this trial
Dimebon 20 mg po TID
Placebo po TID
Sponsors listed in this trial
Pfizer
Medivation, Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services